BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Go back to BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.14 | 52 Week High | $10.98 | |||
| Open | $9.14 | 52 Week Low | $1.63 | |||
| Day High | $9.14 | P/E | N/A | |||
| Day Low | $9.14 | EPS | $-0.68 | |||
| Volume | 15,295 | |||||
